Catalent installing new tableting, encapsulation equipment as part of $40m investment

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Catalent

Catalent is installing new equipment to increase its formulation capabilities and capacity to manufacture controlled-release tablets and capsules.

The $40m investment will see the addition of a laser drill for osmotic drug delivery and stick pack dosage manufacturing capabilities at the company’s Winchester, KY-based facility.

According to the company, it also will increase its roller compaction and fluid bed capacity – and an automated bottling line is currently being installed.

Additionally, a new spray dryer will provide commercial scale-up capacity for projects progressing from early-stage development. This will enable tech transfer of projects from Catalent’s development sites, including San Diego, CA and Nottingham, UK, according to the company.

Equipment validation is expected over the coming months.

Formulation and supply services

In related news, Catalent recently announced that it has successfully provided formulation and supply services for MGB Biopharma’s Phase II clinical trial materials.

Catalent and MGB Biopharma have been working together to formulate and manufacture MGB Biopharma’s leading candidate, MGB-BP-3, an orally-dosed drug for the treatment of Clostridium difficile-associated diarrhea (CDAD).

Also earlier this month, Catalent expanded its hot melt extrusion (HME) capabilities​ at its drug development center of excellence. Additionally, the company opened​ its 30,000-square-foot Shanghai, China-based clinical supply facility, which is expected to employ up to 100.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars